Immunotherapy resistance of lung cancer

Abstract

In recent years, immunotherapy has made remarkable breakthroughs and brought long-term survival benefits to lung cancer patients. However, a high percentage of patients do not respond to immunotherapy or their responses are transient, indicating the existence of immune resistance. Current studies show that the interactions between cancer cells and immune system are continuous and dynamic. A range of cancer cell-autonomous characteristics, tumor microenvironment factors, and host-related influences account for heterogenous responses. Furthermore, with the identification of new targets of immunotherapy and the development of immune-based combinations, we propose the response strategies to overcome resistance.

Keywords

Immunotherapy / resistance mechanisms / response strategies

References

[1] Walsh RJ.Resistance to immune checkpoint inhibitors in non-small cell lung cancer: biomarkers and therapeutic strategies.Ther Adv Med Oncol2020;12:1758835920937902 PMCID:PMC7339077

[2] Boyero L,Alonso M,Molina-Pinelo S.Primary and acquired resistance to immunotherapy in lung cancer: unveiling the mechanisms underlying of immune checkpoint blockade therapy.Cancers (Basel)2020;12:3729 PMCID:PMC7763130

[3] Dearden S,Wu YL.Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap).Ann Oncol2013;24:2371-6 PMCID:PMC3755331

[4] Borghaei H,Horn L.Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer.N Engl J Med2015;373:1627-39 PMCID:PMC5705936

[5] Herbst RS,Kim D.Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.Lancet2016;387:1540-50

[6] Rittmeyer A,Waterkamp D.Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.Lancet2017;389:255-65 PMCID:PMC6886121

[7] Chen DS.Elements of cancer immunity and the cancer-immune set point.Nature2017;541:321-30

[8] Dong ZY,Liu SY.EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer.Oncoimmunology2017;6:e1356145 PMCID:PMC5674946

[9] Wang S,Wang Y.Amphiregulin confers regulatory T cell suppressive function and tumor invasion via the EGFR/GSK-3β/Foxp3 axis.J Biol Chem2016;291:21085-95 PMCID:PMC5076518

[10] Chen N,Zhan J.Upregulation of PD-L1 by EGFR activation mediates the immune escape in EGFR-driven NSCLC: implication for optional immune targeted therapy for NSCLC patients with EGFR mutation.J Thorac Oncol2015;10:910-23

[11] Zhang N,Du W.The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer.Int J Oncol2016;49:1360-8

[12] Gainor JF,Sequist LV.EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis.Clin Cancer Res2016;22:4585-93 PMCID:PMC5026567

[13] Ota K,Kawahara A.Induction of PD-L1 expression by the EML4-ALK oncoprotein and downstream signaling pathways in non-small cell lung cancer.Clin Cancer Res2015;21:4014-21

[14] Coelho MA,Rana S.Oncogenic RAS signaling promotes tumor immunoresistance by stabilizing PD-L1 mRNA.Immunity2017;47:1083-99.e6 PMCID:PMC5746170

[15] Assoun S,Nguenang M.Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.Lung Cancer2019;132:65-71

[16] Dong ZY,Zhang XC.Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma.Clin Cancer Res2017;23:3012-24

[17] George S,Demetri GD.Loss of PTEN is associated with resistance to anti-PD-1 checkpoint blockade therapy in metastatic uterine leiomyosarcoma.Immunity2017;46:197-204 PMCID:PMC5408320

[18] Song MS,Pandolfi PP.The functions and regulation of the PTEN tumour suppressor.Nat Rev Mol Cell Biol2012;13:283-96

[19] Peng W,Liu C.Loss of PTEN promotes resistance to T cell-mediated immunotherapy.Cancer Discov2016;6:202-16 PMCID:PMC4744499

[20] Koyama S,Li YY.STK11/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T-cell activity in the lung tumor microenvironment.Cancer Res2016;76:999-1008 PMCID:PMC4775354

[21] Skoulidis F,Awad MM.STK11/LKB1 co-mutations to predict for de novo resistance to PD-1/PD-L1 axis blockade in KRAS-mutant lung adenocarcinoma.JCO2017;35:9016

[22] Alessi JVM,Ricciuti B,Sholl LM.Clinicopathologic characteristics and immunotherapy outcomes in SMARCA4-mutant (mut) non-small cell lung cancer (NSCLC).JCO2020;38:9577

[23] Yarchoan M,Jaffee EM.Tumor mutational burden and response rate to PD-1 inhibition.N Engl J Med2017;377:2500-1 PMCID:PMC6549688

[24] Chalmers ZR,Fabrizio D.Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.Genome Med2017;9:34 PMCID:PMC5395719

[25] Rizvi NA,Snyder A.Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.Science2015;348:124-8 PMCID:PMC4993154

[26] Le DT,Smith KN.Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.Science2017;357:409-13 PMCID:PMC5576142

[27] Anagnostou V,Forde PM.Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer.Cancer Discov2017;7:264-76 PMCID:PMC5733805

[28] Hulpke S.The MHC I loading complex: a multitasking machinery in adaptive immunity.Trends Biochem Sci2013;38:412-20

[29] Gettinger S,Hastings K.Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer.Cancer Discov2017;7:1420-35 PMCID:PMC5718941

[30] He Y,Rivard CJ.MHC class II expression in lung cancer.Lung Cancer2017;112:75-80

[31] Lastwika KJ,Li QK.Control of PD-L1 expression by oncogenic activation of the AKT-mTOR pathway in non-small cell lung cancer.Cancer Res2016;76:227-38

[32] Reck M,Robinson AG.KEYNOTE-024 InvestigatorsPembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer.N Engl J Med2016;375:1823-33

[33] Ott PA,Hiret S.Pembrolizumab in patients with extensive-stage small-cell lung cancer: results from the phase Ib KEYNOTE-028 study.J Clin Oncol2017;35:3823-9

[34] Gao Y,Bu X.Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy.Nat Cell Biol2020;22:1064-75 PMCID:PMC7484128

[35] Chen X,Zhang W.Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses.Acta Pharm Sin B2020;10:723-33 PMCID:PMC7276686

[36] Thomas A,Trindade C.Durvalumab in combination with olaparib in patients with relapsed SCLC: results from a phase II study.J Thorac Oncol2019;14:1447-57 PMCID:PMC6660419

[37] Guo X,Zheng L.Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing.Nat Med2018;24:978-85

[38] Trefny MP,Uhlenbrock F.A variant of a killer cell immunoglobulin-like receptor is associated with resistance to PD-1 blockade in lung cancer.Clin Cancer Res2019;25:3026-34

[39] Cabrita R,Sanna A.Tertiary lymphoid structures improve immunotherapy and survival in melanoma.Nature2020;577:561-5

[40] Helmink BA,Gao J.B cells and tertiary lymphoid structures promote immunotherapy response.Nature2020;577:549-55

[41] Petitprez F,Keung EZ.B cells are associated with survival and immunotherapy response in sarcoma.Nature2020;577:556-60

[42] Nishikawa H.Regulatory T cells in cancer immunotherapy.Curr Opin Immunol2014;27:1-7

[43] Zou W.Regulatory T cells, tumour immunity and immunotherapy.Nat Rev Immunol2006;6:295-307

[44] Chen C,Zhang Y.Changes of CD4+CD25+FOXP3+ and CD8+CD28- regulatory T cells in non-small cell lung cancer patients undergoing surgery.Int Immunopharmacol2014;18:255-61

[45] Antony PA.CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2.J Immunother2005;28:120-8 PMCID:PMC1242172

[46] Facciabene A,Coukos G.T-regulatory cells: key players in tumor immune escape and angiogenesis.Cancer Res2012;72:2162-71 PMCID:PMC3342842

[47] Rech AJ.Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells.Ann N Y Acad Sci2009;1174:99-106

[48] Bulliard Y,Zhang J,Wilson NS.OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy.Immunol Cell Biol2014;92:475-80

[49] Finotello F.New strategies for cancer immunotherapy: targeting regulatory T cells.Genome Med2017;9:10 PMCID:PMC5273791

[50] Groth C,Weber R.Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression.Br J Cancer2019;120:16-25 PMCID:PMC6325125

[51] Huang B,Li Q.Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host.Cancer Res2006;66:1123-31

[52] Zhao F,Greten TF.Cellular immune suppressor mechanisms in patients with hepatocellular carcinoma.Dig Dis2012;30:477-82 PMCID:PMC3530892

[53] Kim K,Li Z.Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells.Proc Natl Acad Sci U S A2014;111:11774-9 PMCID:PMC4136565

[54] De Henau O,Winkler D.Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells.Nature2016;539:443-7 PMCID:PMC5634331

[55] Chevolet I,Schreuer M.Characterization of the in vivo immune network of IDO, tryptophan metabolism, PD-L1, and CTLA-4 in circulating immune cells in melanoma.Oncoimmunology2015;4:e982382 PMCID:PMC4404886

[56] Li A,Schoenhals JE.Indoleamine 2,3-dioxygenase 1 inhibition targets anti-PD1-resistant lung tumors by blocking myeloid-derived suppressor cells.Cancer Lett2018;431:54-63. PMCID:PMC6027590

[57] Mantovani A,Locati M.Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes.Trends Immunol2002;23:549-55.

[58] Qian BZ,Zhang H.CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis.Nature2011;475:222-5 PMCID:PMC3208506

[59] Negus RP,Relf MG.The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer.J Clin Invest1995;95:2391-6 PMCID:PMC295866

[60] Arenberg DA,DiGiovine B.Macrophage infiltration in human non-small-cell lung cancer: the role of CC chemokines.Cancer Immunol Immunother2000;49:63-70

[61] Lin EY,Russell RG.Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy.J Exp Med2001;193:727-40 PMCID:PMC2193412

[62] Wu Y,Matsushima K,Mukaida N.CCL3-CCR5 axis regulates intratumoral accumulation of leukocytes and fibroblasts and promotes angiogenesis in murine lung metastasis process.J Immunol2008;181:6384-93

[63] Gazzaniga S,Guglielmotti A.Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft.J Invest Dermatol2007;127:2031-41

[64] Dineen SP,Holloway SE.Vascular endothelial growth factor receptor 2 mediates macrophage infiltration into orthotopic pancreatic tumors in mice.Cancer Res2008;68:4340-6

[65] Ries CH,Hoves S.Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy.Cancer Cell2014;25:846-59

[66] Li X,Romero P,Fendt SM.Navigating metabolic pathways to enhance antitumour immunity and immunotherapy.Nat Rev Clin Oncol2019;16:425-41

[67] Tomihara K,Zhang B.Optimization of immunotherapy in elderly cancer patients.Crit Rev Oncog2013;18:573-83 PMCID:PMC3960499

[68] Kugel CH 3rd,Webster MR.Age correlates with response to anti-PD1, reflecting age-related differences in intratumoral effector and regulatory T-cell populations.Clin Cancer Res2018;24:5347-56 PMCID:PMC6324578

[69] Conforti F,Bagnardi V.Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis. Lancet Oncol 2018;19:737-46.

[70] Kichenadasse G,Mangoni AA,Hopkins AM.Association between body mass index and overall survival with immune checkpoint inhibitor therapy for advanced non-small cell lung cancer.JAMA Oncol2020;6:512-8 PMCID:PMC6990855

[71] Califano R,Morgan RD.Immune checkpoint blockade: a new era for non-small cell lung cancer.Curr Oncol Rep2016;18:59

[72] Wang GZ,Zhao XC.The Aryl hydrocarbon receptor mediates tobacco-induced PD-L1 expression and is associated with response to immunotherapy.Nat Commun2019;10:1125 PMCID:PMC6408580

[73] Vétizou M,Daillère R.Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.Science2015;350:1079-84 PMCID:PMC4721659

[74] Routy B,Derosa L.Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.Science2018;359:91-7

[75] Jin Y,Xia L.The diversity of gut microbiome is associated with favorable responses to anti-programmed death 1 immunotherapy in chinese patients with NSCLC.J Thorac Oncol2019;14:1378-89

[76] Atarashi K,Shima T.Induction of colonic regulatory T cells by indigenous Clostridium species.Science2011;331:337-41 PMCID:PMC3969237

[77] Gaboriau-Routhiau V,Lécuyer E.The key role of segmented filamentous bacteria in the coordinated maturation of gut helper T cell responses.Immunity2009;31:677-89

[78] Mazmanian SK,Tzianabos AO.An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system.Cell2005;122:107-18

[79] Ready N,de Braud F.Third-line nivolumab monotherapy in recurrent SCLC: CheckMate 032.J Thorac Oncol2019;14:237-44 PMCID:PMC8050700

[80] Reck M,Lee KH.Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial.Eur J Cancer2019;116:137-47

[81] Rodriguez-abreu D,Hussein MA.Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE). JCO 2020;38:9503-9503.

[82] Bracci L,Sistigu A.Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer.Cell Death Differ2014;21:15-25 PMCID:PMC3857622

[83] Wang Z,Gao Q.Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cells.Oncoimmunology2017;6:e1331807 PMCID:PMC5543863

[84] Gadgeel SM,Esteban E.KEYNOTE-189: Updated OS and progression after the next line of therapy (PFS2) with pembrolizumab (pembro) plus chemo with pemetrexed and platinum vs placebo plus chemo for metastatic nonsquamous NSCLC. JCO 2019;37:9013-9013.

[85] Reck M,Mansfield A.IMpower133: updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC).Ann Oncol2019;30:v710-v711

[86] Socinski MA,Cappuzzo F.IMpower150 Study GroupAtezolizumab for first-line treatment of metastatic nonsquamous NSCLC.N Engl J Med2018;378:2288-301

[87] Neal JW,Felip E.Cabozantinib in combination with atezolizumab in non-small cell lung cancer (NSCLC) patients previously treated with an immune checkpoint inhibitor: results from cohort 7 of the COSMIC-021 study.JCO 2020;38:9610

[88] Gettinger S,Chow LQM.Nivolumab plus erlotinib in patients with EGFR-mutant advanced NSCLC.J Thorac Oncol2018;13:1363-72

[89] Leal TA,Blakely C.Stage 2 enrollment complete: sitravatinib in combination with nivolumab in NSCLC patients progressing on prior checkpoint inhibitor therapy.Ann Oncol2018;29:viii400-1

[90] Antonia SJ,Daniel D.PACIFIC InvestigatorsDurvalumab after chemoradiotherapy in stage III non-small-cell lung cancer.N Engl J Med2017;377:1919-29

[91] Theelen WSME,Lalezari F.Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial.JAMA Oncol2019;5:1276-82 PMCID:PMC6624814

[92] Gettinger SN,Goldberg SB.Clinical features and management of acquired resistance to PD-1 axis inhibitors in 26 patients with advanced non-small cell lung cancer.J Thorac Oncol2018;13:831-9 PMCID:PMC6485248

[93] Schoenfeld AJ,Memon D.Acquired resistance to PD-1 blockade in NSCLC.Ann Oncol2020;38:9621.

[94] Grohé C,Gleiber W.Nintedanib+docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): updated efficacy and safety results of the ongoing non-interventional study (NIS) VARGADO (NCT02392455).Ann Oncol2020;38:9604